VEGFA and Alzheimer disease: Experiments conducted in vitro show that these results may be explained by Aβ-mediated VEGF upregulation, which in turn could leads to reduced sVEGFR levels28, thus implicating that expression levels of sVEGFR2 in endothelial cells may explain modulation of plasma sVEGFR2 levels in patients with AD.